Compare Crispr Therapeutics AG (CRSP) vs Transocean Ltd (RIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Transocean Ltd — how do they compare? Crispr Therapeutics AG trades at $53.51 (market cap $4.88B), while Transocean Ltd trades at $5.53 (market cap $6.19B). The key difference: Transocean Ltd is the larger of the two by market cap, and Transocean Ltd is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Transocean Ltd for 18 Days on average.
| CRSP | RIG | |
|---|---|---|
Market Cap | $4.88B | $6.19B |
Volume | 2,861,747 | 30,564,415 |
Sector | Health | Energy |
52-Week High | $74.92 | $7.58 |
52-Week Low | $44.34 | $3.08 |
Typical Hold Time | 77 Days | 18 Days |
Enterprise Value | $3.30B | $10.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.39, up 1.99% on the day, but remains in a bearish technical trend. The company shows no revenue in 2025, with significant losses (net income margin -4,101.26%) and negative cash flow from operations. However, analyst sentiment is positive with a 57.9% buy rating and a $67.83 consensus price target, citing upcoming clinical data catalysts for its gene-editing therapies like CASGEVY and zugo-cel.
The outlook hinges on successful clinical execution and commercialization of its pipeline. Near-term catalysts include data readouts in autoimmune diseases, but high cash burn, intense competition, and regulatory risks pose substantial challenges. The stock offers high-risk, high-reward potential for investors betting on gene-editing breakthroughs.
Transocean (RIG) trades at $5.55, up 2.97% on the day, with a bullish technical signal driven by oscillators. The company reported a Q2 2026 EPS beat but remains unprofitable with a net income margin of -40.24%. Recent news highlights progress on the $5.8 billion Valaris acquisition and new contract awards, supporting cash flow growth. The stock shows mixed analyst sentiment with a 39.06% buy rating.
The outlook is speculative, hinging on successful deleveraging and offshore cycle strength. Investment opportunity lies in cash flow improvement and backlog execution, but risks include high debt, execution challenges from the Valaris deal, and persistent negative profitability. The stock presents a high-risk, event-driven play for investors betting on an offshore drilling recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →
